MAIO
JUL 0 5 2005 &
EST PARTIES
OCTION .

Substitute	for form 1449A/PTO			Сотр	lete if Known
INFO	DMATION I	DISC	LOSURE	Application Number	10/628,432
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	July 29, 2003
SIAI	(use as many sheets as necessary)		First Named Inventor	C. J. CORCORAN et al.	
			-37	Art Unit	1656
				Examiner Name	William W. Moore
Sheet	Sheet 1 of 4			Attorney Docket Number	031896-036000 (AM101066)

			U.S. PATENT DO	CUMENTS	
Examiner Initials	Cite No.	U.S. Patent Document  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
coam		U.S 4,419,446	12-06-1983	HOWLEY et al.	
work		U.S. – 4,816,567	03-28-1989	CABILLY et al.	

		F	OREIGN PATENT	DOCUMENTS	·	
	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Kind Code <sup>5</sup> Country Code <sup>5</sup> Number <sup>4</sup> (If known)				74
www		EP 0177343 A1	04-19-1985	BOCHNER et al.		
Wor		EP 123289 A2	10-31-1984	BRAKE et al.		
Worth		WO 86/00639 A1	01-30-1986	CLARK et al.		
			i		<b>[</b>	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Wen		AHMED, K. M. et al., Association of an intronic polymorphism in the midkine (MK) gene with human sporadic colorectal cancer, Cancer Lett., 180(2):159-163, 2002	
wwm		AHMED, K. M. et al., Genetic variations of the midkine (MK) gene in human sporadic colorectal and gastric cancers, Int. J. Mol. Med., 6(3):281-287, 2000	
Wim		ARIDOME, K. et al., Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas, Br. J. Cancer, 78(4):472-477, 1998	ı.
wwn		BRANDT, K.D. and MANKIN, H.J., Pathogenesis of Osteoarthritis, in "Textbook of Rheumatology," Kelly, W.N., Harris, E.D., Ruddy, S., and Sledge, C.B. (eds), W.B. Saunders Company, Philadelphia, PA, pp. 1355-1373, 1993	
www		CLARKSON, T. et al., Making antibody fragments using phage display libraries, Nature, 352:624-628, 1991	
(MM		FLANNERY, C.R. et al., Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage, J. Biol. Chem., 267(2):1008-1014, 1992	
www		FOSANG, A.J. et al., Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan, <i>Biochem. J.</i> , 304 (Pt 2):347-351, 1994	
WWM		GETHING, M.J. and SAMBROOK, J., Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene, <i>Nature</i> , 293(5834):620-625, 1981	

Examiner Signature	(lillul)- Moon	Date Considered	18 January 2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>1</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>4</sup> Applicant is to place a check mark here if English language Translation is attached.

Complete if Known Substitute for form 1449A/PTO Application Number 10/628,432 INFORMATION DISCLOSURE July 29, 2003 Filing Date STATEMENT BY APPLICANT C. J. CORCORAN et al. First Named Inventor (use as many sheets as necessary) 1656 Art Unit William W. Moore **Examiner Name** 031896-036000 (AM101066) Attorney Docket Number Of 4 Sheet

Γ		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
www		HARLOW, E. and LANE, D., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988)	
1		HARRIS, W.J., Production of humanized monoclonal antibodies for in vivo imaging and therapy, Biochem. Soc. Trans., 23(4):1035-1038, 1995	
		IKEMATSU, S. et al., Serum midkine levels are increased in patients with various types of carcinomas, Br. J. Cancer, 83(6):701-706, 2000	
		KANAME, T. et al., The expression of truncated MK in human tumors, Biochem.  Biophys. Res. Commun., 219(1):255-260, 1996	
		KADOMATSU, K., Recent progress of midkine research on cancer, Nippon Rinsho, 58(6):1337-1347, 2000	
		KOHLER, G. and MILSTEIN, C., Continuous cultures of fused cells secreting antibody of predefined specificity, <i>Nature</i> , 256(5517):495-497, 1975	
		LAEMMLI, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature, 227(5259):680-685, 1970	
		LEWIS, A.P. and CROWE, J.S., Generation of humanized monoclonal antibodies by best fit framework selection and recombinant polymerase chain reaction, <i>Year Immunol.</i> , 7:110-118, 1993	
		Li, X. et al., Differential protein profile in the ear-punched tissue of regeneration and non-regeneration strains of mice: a novel approach to explore the candidate genes for soft-tissue regeneration, <i>Biochim. Biophys. Acta</i> , 1524(2-3):102-9, 2000	
		Li, X. et al., Analysis of gene expression in the wound repair/regeneration process, Mamm. Genome, 12(1):52-59, 2001	
		LOHMANDER, L.S. et al., The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis, Arthritis Rheum., 36(9):1214-1222, 1993	
		MACLEAN, C.H. et al., Costs attributable to osteoarthritis, J. Rheumatol., 25(11):2213-2218, 1998	
		MANIATIS, T. et al., Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 387-389, 1982	
		MARKS, J.D., By-passing immunization. Human antibodies from V-gene libraries displayed on phage, J. Mol. Biol., 222(3):581-597, 1991	
		MIYASHIRO, I. et al., Expression of truncated midkine in human colorectal cancers, Cancer Lett. 106(2):287-291, 1996	
		MORRISON, S. L. and SCHLOM, J., Recombinant chimeric monoclonal antibodies, in S. A. Rosenberg (ed.), <i>Important Advances in Oncology 3</i> , Lippincott, Philadelphia, PA, 1990	
wwm		OAKLEY, B.R. et al., A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels, Anal. Biochem., 105(2):361-363, 1980	

Examiner Signature	1111 May 12 111	Date Considered	18 January 2006
	0000		<del></del>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitu	te for form 1449A	√PTO		Complete if Known			
INEC	DM ATI	ON DISC	LOSURE	Application Number	10/628,432		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	July 29, 2003				
		First Named Inventor	C. J. CORCORAN et al.				
	(use as many sneets as necessary)			Art Unit	1656		
			Examiner Name	William W. Moore			
Sheet	Sheet 3 Of 4		Attorney Docket Number	031896-036000 (AM101066)			

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.). date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Mora		PAUL, S. et al., Detection of truncated midkine in Wilms' tumor by a monoclonal antibody against human recombinant truncated midkine, Cancer Lett., 163(2):245-251, 2001	
		PAUL, S. et al., Molecular cloning, expression and purification of truncated midkine and its growth stimulatory activity on Wilms' tumor (G401) cells, Cancer Lett., 163(2):239-244, 2001	
	<del></del>	PRESTA, L., Humanized Monoclonal Antibodies, in Annual Reports in Medicinal Chemistry, Academic Press, 1994	
		ROBERTS, S. et al., Matrix turnover in human cartilage repair tissue in autologous chondrocyte implantation, Arthritis Rheum., 44(11):2586-2598, 2001	
	-	SANDY, J.D. et al., Analysis of the catabolism of aggrecan in cartilage explants by quantitation of peptides from the three globular domains, J. Biol. Chem., 266(13):8198-8205, 1991	
		SANDY, J.D. et al., The structure of aggrecan fragments in human synovial fluid.  Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu  373-Ala 374 bond of the interglobular domain. J. Clin. Invest., 89(5):1512-1516, 1992	
		TOWBIN, H. et al., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, Proc. Natl. Acad. Sci. U S A., 76(9):4350-4354, 1979	
		WINTER, G. and MILSTEIN, C., Man-made antibodies, Nature, 349(6307):293-299, 1991	
		International Search Report mailed March 2, 2004, corresponding with International Application PCT/US2003/23483, 4 pages	
		NCBI Annotation Project, XP_123829.midkine [Mus musc[gi:20839708], National Center for Biotechnology Information, 8600 Rockville Pike, Bethesda, MD 20894, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=20839708, 16-MAY-2002	
		Uehara, K. et al., BAA01457.midkine [Homo sapiens[gi:219929], National Center for Biotechnology Information, 8600 Rockville Pike, Bethesda, MD 20894, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=219929, PRI 29-May-1992	
		JAX Mice MRL/MpJ Product Specification, Stock No. 000486, The Jackson Laboratory, Bar Harbor, ME, pages 1-5, March 19, 2002	
V		JAX Mice B6.MRL-Tnfrsf6 <sup>lpr</sup> Product Specification, Stock No. 000482, The Jackson Laboratory, Bar Harbor, ME, pages 1-4, March 19, 2002	
Win		ZHANG, N. and DEUEL, T.F., Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors, <i>Curr. Opin. Hematol.</i> 6(1):44-50, 1999.	

Examiner Signature Munistre Moore Considered 18 January 2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitut	Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE			LOSURE	Application Number	10/628,432	
STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	July 29, 2003			
		First Named Inventor	C. J. CORCORAN et al.			
	(use as many sneets as necessary)			Art Unit	1656	
				Examiner Name	William W. Moore	
Sheet 4 Of 4		Attorney Docket Number	031896-036000 (AM101066)			

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
wwn		HAYNES, H. and RUMSBY, M., The pleiotropin/midkine family of cytokines: role in glial-neuronal signaling, <i>Prog. Brain Res.</i> , 132:313-324, 2001	
4 com		MURAMATSU, T., Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation, <i>Int. J. Dev. Biol.</i> , 37(1):183-188, 1993	
			-

Examiner Signature	Millaile! Marie	Date Considered	18 January 2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>3</sup> See kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



	Substitute for form 1449A/PTO			С	omplete if Known
			COLUMB	Application Number	10/628,432
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Filing Date	July 29, 2003
STAT				First Named Inventor	Christopher CORCORAN
				Art Unit	1614/656
		Examiner Name	Not yet assigned MOOR B		
Sheet	1	of	1	Attorney Docket Number	031896-036000

			U.S. PATENT DOCUM	ENTS	
Examiner Initials	Cite No.	U.S. Patent Document  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	<del> </del>	US-			
		US-			

	FC	DREIGN PATENT D	OCUMENTS	·	
Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant	Τ*
	Country Code <sup>3</sup> Number <sup>4</sup> (if known)	MM-DD-1111	Application of Cited Document	rigures Appear	
		-			
-					
			TED ATURE DOCUMENTS		
	OTHER PRIOR	ART - NON PATENT L	ITERATURE DOCUMENTS		
Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.			T²	
	OI, ET AL., "IMMUNO	GLOBULIN-PRO	DUCING HYBRID CE	LL LINES",	
	SELECTED METHODS I	N CELLULAR IN	MMUNOLOGY, 1980,	PP. 351-372	
	No.1	Cite No.¹  Country Code³ Number⁴ Kind Code³ (if known)  OTHER PRIOR  Cite Include name of the auth item (book, magazine, journal of the control of the contr	Cite No. Solution Date Model Country Code Number (if known)  OTHER PRIOR ART – NON PATENT L  Cite Include name of the author (in CAPITAL LETTER item (book, magazine, journal, serial, symposium, publisher, city and/or of the control	No. 1    No. 1   Name of Patentee or Application Date   Name of Patentee or Application of Cited Document	Cite No.!  Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> MM-DD-YYYY  Application of Cited Document  Name of Patentee or Application of Cited Document  Figures Appear  OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS  Cite No.!  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s),

Examiner Signature	William	(1). More	Date Considered	18 Janua	4 2006

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

MAR 1 5 2004

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known		
Application Number	10/628,432		
Filing Date	July 29, 2003		
First Named Inventor	Christopher John CORCORAN et		
Ari Unit	1681 /656		
Confirmation No.	5325		
Attorney Docket Number	031896-036000		

	U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
11800		US-4,522,811	06/11/1985	Eppstein et al.				
ivour		US-4,554,101	11/19/1985	Норр				

		]	FOREIGN PATENT D	OCUMENTS		
Examiner Initials	Cite No.	Foreign Patem Document  Kind Code  Country Code Number (// known)	Publication Date MM-DD-YYYY	Name of Paternee or Application of Cited Document	Pages, Cohimns, Lines, Where Relevant Passages or Relevant Figures Appear	7*
Win	1	EP 0 123 289	10/31/1984	Brake		Full
Wish		WO 86/00639	01/30/1986	Clark et al.		Full
-		OTHER PRIOR	R ART - NON PATENT	LITERATURE DOCUMENTS	.•	
Examiner Initials	Cite No. <sup>1</sup>			), title of the article (when approp talog, etc.)., date, page(s), volume untry where published.		T²
()/ <sub>U</sub> )h~		Cal et al., "Cloning, expres human ADAMTSs, a famil thrombospondin-1 domains	ly of metalloprotein	nases with disintegrain a		
Mon		Somerville et al., "Characte ADAMTS Subfamily Rela March 14, 2003, Vol. 278,	ted to <i>Caenorhabd</i>	itis elegans GON-1*", J		
(exon.		Kuno et al., "ADAMTS-1." Thrombospondin Type I M 22, May 29, 1998, pp. 139	lotifs and Its Spaci			
linom		Tortorella et al., "Sites of A (ADAMTS-4)*", J. Biol. C				
won		Tortorella et al., "Purificati ADAMTS Family of Prote				
lum		Abbaszade et al., "Cloning the ADAMTS Family*", J. 23450.	and Characterizati Biol. Chem., Vol.	on of ADAMTS11, an 274, No. 3, August 13,	Aggrecanase from 1999, pp. 23443-	·
hyon		Matthews et al., "Brain-enr Glioma Cell Line Is Media Thrombospondin Motifs (A 30, July 28, 2000, pp. 2269	ted by a Disintegrion (DAMTS) Family	n and Metalloproteinase	with	

Examiner Signature MMMWW).	Mwou	Date Considered /8 Journs	2006
			<del></del>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute	Substitute for form 1449A/PTO		Complete if Known		
INEO	INFORMATION DISCLOSURE			Application Number	10/628,432
INFORMATION DISCLOSURE		Filing Date	July 29, 2003		
SIAI	STATEMENT BY APPLICANT		First Named Inventor	Christopher John CORCORAN	
	(use as many sheets	as necesso	עיי)		et al.
				Art Unit	1651 6656
		Examiner Name	5325		
Sheet	2	of	3	Attorney Docket Number	031896-036000

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Inum		Delagrave et al., "Recursive ensemble mutagenesis", Protein Engineering, Vol. 6, No. 3, 1993, pp. 327-331.	!
		Hughes et al., "Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro", Biochem J., 1995, pp. 799-804.	
		Mercuri et al., "Recombinant Human Aggrecan G1-G2 Exhibits Native Binding Properties and Substrate Specificity for Matrix Metalloproteinases and Aggrecanase*", J. Biol. Chem., Vol. 274, No. 45, November 5, 1999, pp. 32387-32395.	
		Miller et al., "An Insect Baculovirus Host-Vector System For High-Level Expression of Foreign Genes", Genetic Engineering, Vol. 8, (Plenum Press 1986), pp. 277-287.	
		Caterson et al., "Mechanisms involved in cartilage proteoglycan catabolism", Matrix Biology, Vol. 19, (2000), pp. 333-344.	
		Kashiwagi et al., "TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)*, J. Biol. Chem., Vol. 276, No. 16, April 20, 2001, pp. 12501-12504.	
		Hashimoto et al., "Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4), FEBS Letters 494, (2001) pp. 192-195.	
		Little et al., "Cyclosporin A Inhibition of Aggrecanase-Mediated Proteoglycan Catabolism in Articular Cartilage", ARTHRITIS & RHEUMATISM, Vol. 46, No. 1, January 2002, pp. 124-129.	·
		Rodríguez-Manzaneque et al., "ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors", Biochemical and Biophysical Research Communications 293 (2002), pp. 501-508.	
		Peppard et al., "Development of a High-Throughput Screening Assay for Inhibitors of Aggrecan Cleavage Using Luminescent Oxygen Channeling (AlphaScreen <sup>TM</sup> ), Society for Biomolecular Screening, (2003) pp. 149-156.	
hum		Gossen et al., "Tight control of gene expression in mammalian cells by tetracycline-responsive promoters", Proc. Natl. Acad. Sci. USA, Vol. 89, June 1992, pp. 5547-5551.	

Examiner Signature	William V	Nou Date Considered	18 January 20036

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known Substitute for form 1449A/PTO 10/628,432 Application Number INFORMATION DISCLOSURE July 29, 2003 Filing Date STATEMENT BY APPLICANT Christopher John CORCORAN et al. First Named Inventor (use as many sheets as necessary) 1654 1656 Art Unit 5325 Examiner Name Sheet of Attorney Docket Number 031896-036000

·		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Initials* No.1 item (book, magazine, journal, serial, symposiu publisher, city and/		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
wwn		Urlaub et al., "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity", Proc. Ntl. Acad. Sci. USA, Vol. 77, No. 7, July 1980, pp. 4216-4220.	
1		Gill et al., "Calculation of Protein Extinction Coefficients from Amino Acid Sequence Data", Analytical Biochemistry 182, (1989) pp. 319-326.	
		Flannery et al., "Autocatalytic Cleavage of ADAMTS-4 (Aggrecanase-1) Reveals Multiple Blycosaminoglycan-binding Sites*", J. Biol. Chem., Vol. 277, No. 45, November 8, 2002, pp. 42775-42780.	
		Okayama et al., "High-Efficiency Cloning of Full-Length cDNA", Molecular and Cellular Biology, Vol. 2, No. 2, February 1982, pp. 161-170.	
		Gough et al., "Structure and expression of the mRNA for murine granulocyte-macrophage colony stimulating factor", EMBO Journal, Vol. 4, No. 3, 1985, pp. 645-653.	
		Wong et al., "Human GM-CSF: Molecular Cloning of the Complementary DNA and Purification of the Natural and Recombinant Proteins", SCIENCE, Vol. 228, May 17, 1985, pp. 810-815.	
		Kaufman, "Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors", Proc. Nat. Acad. Sci. USA, Vol. 82, February 1985, pp. 689-693.	
		Morinaga et al., "Improvement of Oligonucleotide-Directed Site-Specific Mutagenesis Using Double-Stranded Plasmaid DNA", BIO/TECHNOLOGY, July 1984, pp. 636-639.	
		Jang et al., "Initiation of Protein Synthesis by Internal Entry of Ribosomes into the 5' Nontranslated Region of Encephalomyocarditis Virus RNA In Vivo", J. Virology, Vol. 63, No. 4, April 1989, pp. 1651-1660.	
	,	Taniguchi et al., "Expression of the human fibroblast interferon gene in Escherichia coli*", Proc. Natl. Acad. Sci. USA, Vol. 77, No. 9, September 1980, pp. 5230-5233	
		Kaufman et al., "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene", J. Mol. Biol. (1982) 159, pp. 601-621.	
$\bigvee$		Kaufman et al., "Construction of a Modular Dihydrofolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression", Molecular and Cellular Biology, Vol. 2, No. 11, November 1982, pp. 1304-1319.	
lvwn		Littlefield et al., "Selection of Hybrids from Matings of Fibroblasts in vitro and Their Presumed Recombinants", August 14, 1964, Vol. 145, pp. 709.	-

Examiner	11,	11 11/1		Date ·	101	0
Signature		uull // U	wor	Considered	18 Ja	ullus 606

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALLE 29 THE STATE OF THE PARTY OF THE PARTY

Complete if Known Substitute for form 1449A/PTO 10/628,432 **Application Number** INFORMATION DISCLOSURE July 29, 2003 Filing Date STATEMENT BY APPLICANT C. J. CORCORAN et al. First Named Inventor (use as many sheets as necessary) 1656 Art Unit **Examiner Name** William W. Moore 031896-036000 (AM101066) Sheet of 1 Attorney Docket Number U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Relevant Cite No.1 **Publication Date** Name of Patentee or Examiner U.S. Patent Document Applicant of Cited Document Passages or Relevant Figures Appear MM-DD-YYYY Number - Kind Code<sup>3</sup> (if known) FOREIGN PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where Foreign Patent Document Examiner **Publication Date** Relevant Passages or Relevant MM-DD-YYYY Applicant of Cited Document T٥ Country Code<sup>3</sup> Number<sup>4</sup> (if known) OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS T² Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner item (book, magazine, journal, serial, symposium, catalog, etc.)., date, page(s), volume-issue number(s), publisher, city and/or country where published. International Search Report for PCT/US2003/23484, mailed March 2, 2004, 4 pages

Examiner Signature	Milleury)	Nwow	Date Considered	18 January	2006
		<del></del>			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

MAY 1 8 2004 E

## Complete if Known Substitute for form 1449A/PTO 10/628,432 Application Number INFORMATION DISCE July 29, 2003 Filing Date STATEMENT BY APPLICANT Christopher CORCORAN First Named Inventor (use as many sheets as necessary) 1614 /656 Art Unit Not yet assigned MOOKE Examiner Name Sheet of Attorney Docket Number 031896-036000

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. 1	U.S. Patent Document  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Win		US-2002/0090373 A1	07-11-2002	Buckbinder et al.	rigues Appea
aron	-	US-2003/0073116 A1	04-17-2003	Ginsburg et al.	
_		US-	<u> </u>		

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Kind Code  Country Code  Number  (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
Woh		WO 00/53774 A3	09-14-2000	Kelner et al.		
		OTHER PRIOR A	ART – NON PATENT I	ITERATURE DOCUMENTS		
Examiner Initials					T <sup>2</sup>	
			,		-	
						1

Examiner	11.11	Date	101
Signature	Mulland). VI	1170 Ce Considered	18 Jonnes 2006
	- 17-6-6-5-17-10-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1	7.1777 CC	1 ocoming 2000

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached